TRANSGENE Announces a Follow-on Investment in Jennerex, Inc.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG), a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announces an additional $2.5 million investment in the equity capital of Jennerex, Inc. The investment was made in the context of a $21.6 million private placement of shares to existing shareholders of the Company. The proceeds will notably be used for the financing of ongoing clinical studies with Pexa-Vec (JX549/TG6006), developed in collaboration with Transgene.
Help employers find you! Check out all the jobs and post your resume.
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG), a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announces an additional $2.5 million investment in the equity capital of Jennerex, Inc. The investment was made in the context of a $21.6 million private placement of shares to existing shareholders of the Company. The proceeds will notably be used for the financing of ongoing clinical studies with Pexa-Vec (JX549/TG6006), developed in collaboration with Transgene.
Help employers find you! Check out all the jobs and post your resume.